FMP
Nov 10, 2021(Last modified: Dec 19, 2023)
Nevro Corp. (NYSE:NVRO) shares closed 3.50% lower on Tuesday, following the company’s reported Q3 results, with an EPS of ($0.87), almost in line with the consensus estimate. Quarterly revenues decreased 14.1% year-over-year to $93.2 million, better than the consensus estimate by 2.1%.
The company provided its Q4 outlook, expecting revenue of $94-98 million, below the consensus estimate of $112 million.
Analysts at Oppenheimer provided the following key points on the company:
(1) Soft outlook expected to continue into 1H22,
(2) Logistics of DTC in PDN is unclear, especially the role of endocrinologists in the process,
(3) How growth in PDN will hold up when the CBP market is slowing is unclear,
(4) Company commentary reflecting challenges in an otherwise-flattish market. Commentary on growth returning in 2H22 is bound to raise concerns.

In times of rising geopolitical tension or outright conflict, defense stocks often outperform the broader market as gove...

As Circle Internet (NYSE:CRCL) gains attention following its recent public listing, investors are increasingly scrutiniz...

LVMH Moët Hennessy Louis Vuitton (OTC:LVMUY) is a global leader in luxury goods, offering high-quality products across f...